Scarica l'app Stockscreener
10.99
12.29%
-1.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Novocure Ltd Borsa (NVCR) Ultime notizie
Novocure wins FDA approval to treat pancreatic cancer with electric fields - MedTech Dive
NovoCure (NASDAQ:NVCR) Trading Down 6.5%Here's What Happened - MarketBeat
Is NovoCure (NVCR) Pricing Reflect Long Term Potential After Recent 24% Weekly Jump - simplywall.st
NovoCure (NVCR) Is Up 23.6% After Landmark FDA Nod For Optune Pax In Pancreatic Cancer - Yahoo Finance
NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval - Blockonomi
Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
NovoCure (NVCR) Stock Soars Following Pancreatic Cancer Treatment Approval - CoinCentral
NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN
What is NovoCure Limited’s book value per share2025 EndofYear Setup & Free Verified High Yield Trade Plans - mfd.ru
Approval for pancreatic cancer treatment boosts Novocure - גלובס
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer - Yahoo Finance
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47 | - GuruFocus
NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga
Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment - Medical Product Outsourcing
Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED) - Benzinga
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright By Investing.com - Investing.com India
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright - Investing.com
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax - GuruFocus
U.S. Stock Futures Rise as Fastly and Novocure Surge - Intellectia AI
Novocure shares surge after FDA approves pancreatic cancer device By Investing.com - Investing.com South Africa
Novocure shares surge after FDA approves pancreatic cancer device - Investing.com India
Form 8-KMaterial Events - Stock Titan
First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan
Novocure shares soar 30% after FDA nod for pancreatic cancer device - Investing.com Australia
FDA Approves Novocure's Optune Pax for Pancreatic Cancer Treatme - GuruFocus
NovoCure Ltd treatment gains FDA approval for pancreatic cancer - Traders Union
Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer - TradingView
FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer - Stock Titan
NovoCure (NVCR) Stock Is Trending OvernightHere's What You Should Know - Bitget
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story - Sahm
HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings - Defense World
HC Wainwright Has Negative View of NovoCure FY2029 Earnings - MarketBeat
Novocure stock hits 52-week low at $10.66 By Investing.com - Investing.com South Africa
C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR - MarketBeat
Novocure stock falls after CMS revokes billing privileges By Investing.com - Investing.com South Africa
Novocure stock falls after CMS revokes billing privileges - Investing.com
NovoCure (NASDAQ:NVCR) Sets New 52-Week LowWhat's Next? - MarketBeat
Novocure stock hits 52-week low at $10.66 - Investing.com
**NovoCure Faces CMS Billing Privileges Revocation** - TradingView
Take Profit: Is NovoCure Limited stock showing strong momentumTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Piper Sandler reiterates Overweight rating on NovoCure stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on NovoCure stock - Investing.com
Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR) Stock Analysis: An Investor’s Look at 81.53% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR): Investor Outlook on a 76% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews
1.33%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):